<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336404">
  <stage>Registered</stage>
  <submitdate>11/01/2011</submitdate>
  <approvaldate>13/01/2011</approvaldate>
  <actrnumber>ACTRN12611000043932</actrnumber>
  <trial_identification>
    <studytitle>C-reactive protein response to newborn hepatitis B immunisation</studytitle>
    <scientifictitle>C-reactive protein response to newborn hepatitis B immunisation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Concentration of C-reactive protein in blood after hepatitis B immunisation</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Term babies born by elective caesarean section are randomised to recieve routine intramuscular monovalent hepatitis B immunisation (0.5mL of H-B-Vax II, CSL Biotherapies/Merck &amp; Co Inc, containing 5 micrograms of hepatitis B surface antigen adsorbed onto 0.25 mg of aluminium hydroxide in 0.5 mL) either at 24 or after 96 hours of age. Daily CRP levels are taken at 24, 48, 72 and 96 hours. Administration of vaccine at either 24 or 96 hours is within standard practice.</interventions>
    <comparator>All babies recieve standard treatment, namely immunisation with monovalent hepatitis B vaccine within the first week of life. In one group (the control group) vaccine is given slightly later. The comparison is the effect on CRP concentrations between normal dose and no dose of hepatitis B vaccine in the first 96 hours of life.</comparator>
    <control>Active</control>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Concentration of CRP in blood</outcome>
      <timepoint>CRP concentrations measured at 24, 48, 72 and 96 hours of life</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Gestation 37-40 weeks
Elective caesarean section without labour or membrane rupture
Well at 24 hours of age
Parental intention to give birth dose of hepatitis B vaccine</inclusivecriteria>
    <inclusiveminage>24</inclusiveminage>
    <inclusiveminagetype>Hours</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Hours</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Gestation &lt;37 weeks or &gt;40 weeks
Unwell at 24 hours of age
Parents don't intend to give birth dose of hepatitis B vaccine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>At 24 hours of age, babies were randomised to a treatment group by opening sequentially numbered opaque envelopes.</concealment>
    <sequence>A randomisation sequence was developed before the start of the study by placing a single slip of paper labelled either Immunisation or Control (6 slips, 3 of each treatment, block length 6) into each of 6 identical opaque envelopes, sealing the envelopes, shuffling and then numbering the envelopes sequentially. The process was repeated in blocks of 6 until the required total number of envelopes (40 envelopes numbered 1-40) was assembled.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>12/12/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>42</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Scott Morris</primarysponsorname>
    <primarysponsoraddress>Centre for Perinatal medicine
Flinders Medical Centre
Flinders Drive
Bedford Park
South Australia
5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Flinders Medical Centre</fundingname>
      <fundingaddress>Flinders Drive
Bedford Park
South Australia
5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Canberra Hospital</fundingname>
      <fundingaddress>Yamba Drive
Garran
ACT
2605</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>CRP may be useful in the newborn period as an infection screen. Universal hepatitis B immunisation may limit the usefulness of CRP if an inflammatory response is induced. This study looks at CRP response after birth in a group of babies where infection can definitely be excluded. Babies are randomised to recieve vaccination at either 24 hours of age or after 96 hours. A CRP level is taken each day and the levels in the 2 groups are compared.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ACT Health and Community Care Human research Ethics Committee</ethicname>
      <ethicaddress>GPO Box 825
Canberra
ACT
2601</ethicaddress>
      <ethicapprovaldate>15/10/2001</ethicapprovaldate>
      <hrec>ETH.9/01.323</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Adelaide Health Service/Flinders University Human Research Ethics committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Flinders Drive
Bedford Park
South Australia
5042</ethicaddress>
      <ethicapprovaldate>25/03/2002</ethicapprovaldate>
      <hrec>30/02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Scott Morris</name>
      <address>Centre for Perinatal Medicine
Flinders Medical Centre
Bedford Park
South Australia
5042</address>
      <phone>618 82044595</phone>
      <fax>618 82043143</fax>
      <email>scott.morris@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Scott Morris</name>
      <address>Centre for Perinatal Medicine
Flinders Medical Centre
Flinders Drive
Bedford Park
South Australia
5042</address>
      <phone>618 82044595</phone>
      <fax>618 82043143</fax>
      <email>scott.morris@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Scott Morris</name>
      <address>Centre for Perinatal Medicine
Flinders Medical Centre
Bedford Park
South Australia
5042</address>
      <phone>618 82044595</phone>
      <fax>618 82043143</fax>
      <email>scott.morris@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>